Novartis’s first-quarter core net income fell 4 percent, it said on Tuesday, as the Swiss drugmaker’s spending to kick start sales at its eyecare unit Alcon and for its heart failure drug
Entresto weighed again on earnings.
Core net income fell to $2.69 billion, Novartis said, beating the $2.67 billion average forecast of analysts in a Reuters poll.
